S&P 500   4,486.46
DOW   35,258.61
QQQ   372.65
S&P 500   4,486.46
DOW   35,258.61
QQQ   372.65
S&P 500   4,486.46
DOW   35,258.61
QQQ   372.65
S&P 500   4,486.46
DOW   35,258.61
QQQ   372.65
CNSX:VRT

Vertiv Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume2,475 shs
Average Volume73,073 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Receive VRT News and Ratings via Email

Sign-up to receive the latest news and ratings for Vertiv and its competitors with MarketBeat's FREE daily newsletter.


About Vertiv

Veritas Pharma Inc., through its subsidiary, Cannevert Therapeutics Ltd. operates as a pharmaceutical and IP development company. It develops proprietary cannabis strains for chronic and acute pains, nausea and vomiting, and post-traumatic stress disorders. The company was formerly known as Seashore Organic Medicine Inc. and changed its name to Veritas Pharma Inc. in December 2015. Veritas Pharma Inc. was incorporated in 2014 and is headquartered in Vancouver, Canada.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Employees
20,972
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A

Profitability

Debt

Price-To-Earnings

Miscellaneous

Next Earnings Date
N/A
Optionable
Not Optionable

MarketRank

Overall MarketRank

0.88 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












Vertiv (CNSX:VRT) Frequently Asked Questions

What stocks does MarketBeat like better than Vertiv?

Wall Street analysts have given Vertiv a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Vertiv wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Who are Vertiv's key executives?

Vertiv's management team includes the following people:
  • Mr. Lorne Mark Rosenborough, CEO & Chairman (Age 68)
  • Mr. Peter McFadden B.Com., B.Sc., C.A., C.P.A., M.B.A., Chief Financial Officer (Age 64, Pay $120k)
  • Mr. Blair Curtis Lowther, Corp. Sec. & Director (Age 43, Pay $60k)
  • Ms. Barbara J. Joe, Controller

What other stocks do shareholders of Vertiv own?

What is Vertiv's stock symbol?

Vertiv trades on the CNSX under the ticker symbol "VRT."

How do I buy shares of Vertiv?

Shares of VRT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

How many employees does Vertiv have?

Vertiv employs 20,972 workers across the globe.

What is Vertiv's official website?

The official website for Vertiv is www.veritaspharmainc.com.

Where are Vertiv's headquarters?

Vertiv is headquartered at 1050 Dearborn Drive, Columbus, Ohio 43085.

How can I contact Vertiv?

Vertiv's mailing address is 1050 Dearborn Drive, Columbus, Ohio 43085. The company can be reached via phone at 16148880246.


This page was last updated on 10/19/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.